Stronger Exelon Patch Wins FDA Nod

A transdermal patch delivering rivastigmine (Exelon) at a 40% higher rate than the previous maximum strength has been cleared by the FDA for patients with mild to moderate Alzheimer’s disease, its manufacturer said. The newly approved patch provides 13.3 mg of the drug over 24 hours, according to Novartis. Formulations delivering 9.5 and 4.6 mg per 24 hours were previously approved.
MedPage Today